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ABSTRACT

Kiesel, Violet A. M.S., Purdue University, December 2016. Diallyl Trisulfide Modulates
Notch Pathway Components in Breast Cancer Cells. Major Professor: Dr. Silvia D. Stan.

Breast cancer affects one in eight women throughout the course of their lifetimes
creating an immediate demand for novel prevention strategies against this disease. The
Notch signaling pathway is often aberrantly activated in human malignancies including
breast cancer. Alpha secretases, including A Disintegrin and Metalloprotease (ADAM)10 and -17, are proteases that play a key role in the cleavage of cell surface molecules
and subsequent ligand-mediated activation of Notch signaling pathway. High expression
levels of ADAM10 are clinically associated with lower disease-free survival in breast
cancer patients. The goal of this study was to determine the effect of diallyl trisulfide
(DATS), a bioactive organosulfide found in garlic and other Allium vegetables, on Notch
pathway components, specifically alpha secretases, in an in vitro model of breast cancer.
Here we report for the first time that DATS inhibits the expression of ADAM10 and
ADAM17 in estrogen-independent MDA-MB-231 and estrogen-dependent MCF-7 breast
cancer cells, as well as in Harvey-ras (H-Ras) transformed MCF10A-H-Ras breast
epithelial cells. We also show that DATS inhibits the Notch ligands Jagged-1 and
Jagged-2. Furthermore, we show that DATS treatment reduces overall cell viability in
MDA-MB-231, MCF-7 and MCF10A-H-Ras cells, and that DATS treatment reduces

x
viability of normal-like breast epithelial MCF-12A cells to a lesser extent. DATS
induces a dose-dependent reduction in colony formation ability of MDA-MB-231 and
MCF-7 breast cancer cells. Collectively, our results show that DATS modulates Notch
pathway components deregulated in breast cancer cells and may serve as a functionally
relevant bioactive for breast cancer prevention.
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CHAPTER 1. INTRODUCTION

1.1

Introduction to Breast Cancer

Cancer remains a major public health concern in 2016. An estimated 1.68 million
new cases of cancer will be diagnosed in the US in 2016, with nearly a quarter of a
million cases coming from breast cancer (1). Breast cancer has a one-in-eight lifetime
risk in women and is projected to result in nearly 41,000 deaths in 2016 (1). The
incidence of breast cancer among women has varied over the past forty years. A sharp
increase in diagnoses occurred throughout the 1980s and 1990s, an effect largely
attributed to the increased prevalence of mammography at that time (2). Conversely,
incidence dropped considerably from 2002-2003 following publication of a report linking
use of menopausal hormones with increased risk of breast cancer (3–5). Since this time,
breast cancer incidence in the US has remained relatively stable.
Breast cancer is frequently classified based on the presence or absence of clinically
significant molecular markers expressed in the tumor tissue, including hormone receptors
and human epidermal growth factor receptor 2 (HER2) (6,7). This classification system
groups breast cancer patients into four major categories (Table 1.1). The first category is
Luminal A, which is positive for estrogen receptor (ER) and/or progesterone receptor (PR)
and does not overexpress HER2. Luminal B breast cancer is positive for ER and/or PR
and also overexpresses HER2. HER2+ breast cancer displays overexpression of HER2
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Table 1.1 Sub-classifications of breast cancer based on expression of clinically significant
molecular markers.
Classifications of breast cancer subtypes based on presence or absence of estrogen
receptor, progesterone receptor, and HER2. + symbol in table indicates positive
expression of molecular marker, - symbol in table indicates negative expression of
molecular marker. Adapted from reference (7).
Estrogen/
Molecular Subtype
Progesterone
HER2
Receptor
Luminal A
+
Luminal B
+
+
HER2+
+
Triple-Negative
-

but absence of both hormone receptors. Finally, triple negative breast cancer lacks
expression of ER, PR, and HER2. Luminal A breast cancer is both the most commonly
occurring type of breast cancer and the most favorable in prognosis, as the presence of
hormone receptors makes these cancer cells susceptible to hormone-focused treatment
strategies (7). HER2+ breast cancer represents 4% of all breast cancer cases and has a
favorable prognosis due to the clinical efficacy of trastuzumab, a monoclonal antibody
which targets HER2 (7). Triple-negative breast cancer accounts for 12% of breast cancer
cases and currently lacks a targeted treatment strategy (7).
Heterogeneity in cancer dictates treatment strategies and plays a role in predicting
survival. Intertumor heterogeneity, the variability in the molecular signature between
two patients, determines the appropriate drugs for treating individual patients (7).
Intratumor heterogeneity, defined as the variability of molecular subtypes within a single
tumor, presents a unique set of challenges (8). First, a single biopsy of the primary tumor
may not capture the full diversity of molecular signatures represented in the tumor, as
shown by Gerlinger et al. in a study of renal-cell carcinoma (9). This shortcoming of
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biopsies can lead to improper treatment selection if not all subclones within the tumor
were identified by biopsy. Improper or inadequate treatment can then induce a shift in
dominance to unaffected subclones and permit survival of the tumor (8). Intratumor
heterogeneity also permits intermetastatic heterogeneity, or the heterogeneity between
different metastatic lesions within a single patient (10). The presence of many clones
within the primary tumor creates variation in molecular signatures at metastatic lesions,
decreasing the probability of effectively treating the cancer at each site (10). One
solution to the challenges of heterogeneity in cancer is the use of multiple targeted anticancer drugs in tandem to maximize cancer cell kill. Polypharmacy, however, has its
own set of challenges including patient burden and drug-drug interactions (11).
Epidemiological data has long suggested a correlation between specific foods and
food groups and risk of cancer. Consumption of whole fruits and vegetables is associated
with protection from several types of cancer, including breast cancer (12). More
specifically, epidemiological research examining consumption of cruciferous vegetables,
soy, green tea, red wine, and Allium vegetables including garlic and onions (12–17) has
identified inverse relationships between consumption of these specific foods and
development of cancer. Consumption of Allium vegetables was inversely associated
with breast cancer development in a case-control study completed in Lorraine, France
(17). Women consuming 11-12 servings of garlic and onions per week had an adjusted
odds ratio of 0.25 (95%CI: 0.11-0.55, P-value < 10-6) for breast cancer compared to
women consuming ≤ 6 weekly servings (17). A case-control study conducted in Italy and
Switzerland reported an odds ratio of 0.75 (95%CI: 0.50-1.12, P-value = 0.08) for breast
cancer among women consuming ≥ 7 weekly servings of onions compared to non-
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consumers (18). An inverse association between garlic consumption and cancer
incidence was also found in a meta-analysis of stomach and colorectal cancers (19). The
results collectively suggest a protective role of Allium vegetables in development of
multiple types of cancer, including breast cancer.

1.2

Synthesis and Pharmacokinetics of Diallyl Trisulfide

Diallyl trisulfide (DATS) has been identified as one of the most bioactive
components of the Allium vegetable garlic (20). Below we discuss synthesis,
pharmacokinetics, and mechanisms of action of DATS in cancer cells.
DATS is synthesized from its precursor, gamma-glutamyl-S-allyl-L cysteine, which
is naturally present in the garlic clove (Figure 1.1) (21,22). Gamma-glutamyl-S-allyl-L
cysteine can convert to S-allyl cysteine, a water-soluble and non-volatile compound with
antioxidant properties (21–23). It can also convert to alliin, with gradual accumulation of
alliin occurring throughout storage of intact cloves (21). Crushing or chewing liberates
alliinase from the bundle sheath cells of the clove, allowing it to convert alliin to allicin
(21,23,24). Allicin is unstable and spontaneously decomposes to lipid-soluble
organosulfides including DATS, among others (21,24). Alliin accounts for
approximately 1% of whole garlic and is odorless; its enzymatic product allicin, however,
has the pungent aroma characteristic of fresh garlic (21,24). DATS, too, is a volatile
compound (24). DATS is more abundant than its related compounds, diallyl disulfide
and diallyl sulfide, with an estimated 900-1100 μg of DATS per g of garlic (25,26). A
typical 5 g clove of garlic may then contain 5 mg of DATS.

5

Figure 1.1 Synthesis of diallyl trisulfide and related organosulfides.
Adapted from reference (22).

Pharmacokinetic data on DATS in humans is sparse and critically needed. Animal
models, however, provide some insight on DATS pharmacokinetics. For example, a 10
mg injection of DATS administered to the jugular vein in rats resulted in 30 μmol/L
maximum DATS concentration in the blood (27). Concentrations of DATS rapidly
peaked one minute following the injection, and progressively decreased over 24 h (27).
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Methods of extending the half-life of DATS in the blood have been attempted.
Incorporation of DATS into a microemulsion prior to a 30 mg/kg intravenous injection in
Sprague Dawley rats increased the maximum concentration of DATS in blood to
approximately 40 μmol/L, compared to 30 μmol/L achieved without the microemulsion
(27,28). The Tmax of DATS following the microemulsion injection was 3 h (28). In
humans, oral consumption of up to 25 g of raw, chopped garlic did not result in
detectable levels of allicin, DATS, or other organosulfides in the blood or urine 1, 2, 4, or
24 h after consumption (29). Given that the Tmax of DATS administered directly to the
blood of rats was one minute (27), testing human blood one hour after garlic ingestion
may not have captured peak concentrations of DATS. Ingestion of DATS may result in
storage of DATS in the liver or other organs. The possibility of DATS storage in organ
tissue is supported by the observation that vinyl dithiins, a product of allicin degradation,
is stored in the livers of rats (30). Further pharmacokinetic data are critically needed.

1.3

Clinical Trial of Diallyl Trisulfide

In a clinical trial completed in China, approximately 5000 men and women were
randomized to orally consume 200 mg of DATS every day and 100 μg of selenium every
other day for the month of November in 1989, -90, and -91 (31). Subjects were age 3574 y and had a medical history of stomach disorders, family history of cancer, smoked or
consumed alcohol, or had some combination of these four inclusion criteria. Five years
after completion of the intervention, there was a 22% decrease in morbidity rate of all
cancers and a 47% decrease in the rate of gastric cancer in those receiving DATS and
selenium compared to control subjects. Relative risks for both genders combined
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following intervention were 0.67 for all cancers (95%CI: 0.43-1.03) and 0.48 for stomach
cancer (95%CI: 0.21-1.06). Among men, the relative risks were 0.51 (95%CI: 0.30-0.85)
for all cancers and 0.36 (95%CI: 0.14-0.92) for stomach cancer. Among women, the
intervention did not significantly modulate cancer risk. The researchers noted that this
may be a result of a smaller sample size for women compared to men (n=3250 for men,
n=1783 for women) or the lower incidence of gastric cancer among women (31). The
results of this clinical trial highlight the safety of oral DATS administration for a
prolonged period of time and may suggest a role for DATS in cancer chemoprevention.
The safety and anticancer effect of DATS have also been identified in animal models of
cancer.

1.4

Mechanisms of Action of Diallyl Trisulfide in vivo and in vitro

Animal models of cancer exemplify the safety and efficacy of DATS against cancer
cell growth. MCF-7 breast cancer xenograft nude mice, for example, upon receiving 5
μmol/kg body weight DATS by oral gavage twice weekly for one month, displayed
reduced tumor volume 3 months following inoculation compared to control-treated mice
(32). DATS treatment also reduced tumor size in PC-3 prostate cancer xenograft animals
(33). Importantly, treating SUM159 breast cancer xenograft mice with 2 mg DATS three
times weekly did not decrease body weight (34), suggesting DATS is non-toxic to major
organs.
The anticancer effect of DATS has been researched in cell culture models of
pancreatic, stomach, colon, prostate, and breast cancer, among others (35–39). DATS
treatment generates reactive oxygen species in cancer cells (39–41). DATS-mediated
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reactive oxygen species generation was inhibited by overexpression of the c-Jun Nterminal Kinase (JNK) inhibitor JNKK2 in DU145 prostate cancer cells, suggesting that
DATS induces activation of JNK and subsequent generation of reactive oxygen species
(40). JNK activation, however, was inhibited by the antioxidant N-acetylcysteine in
MCF-7 breast cancer cells, indicating that reactive oxygen species may play a role in
JNK activation (32). Generation of reactive oxygen species following DATS treatment is
associated with induction of apoptosis and cell cycle arrest in cancer cells.
DATS is a known inducer of apoptosis in cultured cancer cells. DATS treatment
induced de-activating phosphorylation of the anti-apoptotic protein Bcl-2 in cultured
prostate cancer cells (42). Increased Bcl-2 phosphorylation was also observed in tumors
from PC-3 prostate cancer xenograft mice treated with 6 μmol DATS, delivered three
times a week by oral gavage (33). Phosphorylation of Bcl-2 by DATS was suppressed by
the JNK inhibitor SP600125 in prostate cancer and breast cancer cells (32,42). The effect
of DATS on apoptosis was blunted following addition of N-acetylcysteine or
overexpression of catalase (41,42). In cell models of breast cancer, DNA fragmentation
was observed in estrogen-independent MDA-MB-231 and estrogen-dependent MCF-7
breast cancer cells following DATS treatment (39), suggesting that DATS induces
apoptosis independent of ER status. The data collectively suggest that DATS treatment
induces apoptosis in multiple types of cancer, is associated with JNK activation and
reactive oxygen species generation, and is independent of hormone receptor status in
breast cancer cells.
DATS treatment induces cell cycle arrest in cancer cells. Specifically, cell models
show G2/M cell cycle arrest in response to DATS treatment (37,43). Importantly, G2/M
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cell cycle arrest was not observed in normal prostate epithelial cells cultured with DATS
at a similar concentration (43). DATS decreased expression of Cdc25C and induced
expression of cyclin B1, both of which play a role in entry to mitosis (43,44). DATSmediated cell cycle arrest was attenuated by co-treatment with N-acetylcysteine as well
as knock-down of checkpoint kinase-1 in prostate cancer cells (43,45). The results
indicate that DATS induces G2/M cell cycle arrest in cancer cells, and is associated with
reactive oxygen species generation.
DATS also plays a role in reducing cell migration and invasion, and the cancer stem
cell (CSC) population. DATS treatment reduced passage of MDA-MB-231 cells through
Transwell chambers and delayed wound healing in an in vitro scratch assay (46,39).
DATS treatment induced expression of the cell-cell adhesion protein E-cadherin and
suppressed vimentin and matrix metalloproteases-2 and -9, collectively suggesting a role
for DATS in suppression of cancer cell migration and invasion (46,39). Most recently,
DATS treatment was shown to inhibit the CD44high/CD24low/ESA+ sub-population of
estrogen-dependent MCF-7 and triple-negative SUM159 breast cancer cells, as well as
sphere formation in both cell lines (34). Aldehyde dehydrogenase-1 (ALDH1) activity
was inhibited by DATS treatment in vitro and in vivo (34). The combined results suggest
that DATS can target the breast CSC population (34). Inhibition of breast CSCs by
DATS was mediated by inhibition of FoxQ1 in SUM159 cells, although the near absence
of FoxQ1 protein in MCF-7 cells suggests other mechanisms may contribute to CSC
inhibition by DATS (34).
Several other pathways may contribute to CSC inhibition by DATS. Embryonic
signaling pathways, including Hedgehog, Wnt/β-catenin, and Notch, are often aberrantly
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activated in cancer cells and can contribute to CSC self-renewal. In cultured U2OS,
SaOS-2, and MG-63 osteosarcoma cells, DATS down-regulated expression of the
cleaved Notch-1 receptor and the downstream Notch targets Hes-1, Hey-1, and cyclin D1
(47).

1.5

Notch Signaling Pathway and Clinical Significance

The Notch signaling pathway, while indispensable in embryonic development,
plays a key role in tumor growth in several types of cancer, including breast cancer (48–
50). In addition to its role in cell proliferation, Notch regulates angiogenesis, the
epithelial to mesenchymal transition (EMT), and the CSC population in tumor cells (51–
53). The many diverse downstream processes regulated by Notch highlight this pathway
as a potential therapeutic target in cancer.
Notch is a type of juxtacrine signaling pathway which requires direct contact
between neighboring cells for pathway activation (Figure 1.2) (54). Notch ligands,
including Jagged-1, Jagged-2, and Delta-like (DLL)-1, -3, and -4, are expressed on the
signal-sending cell, and physically interact with Notch receptors (Notch-1, -2, -3, -4) on
neighboring signal-receiving cells. Binding of a Notch ligand to a Notch receptor
induces a conformational change in the receptor which permits A Disintegrin and
Metalloprotease (ADAM)-10 to cleave the Notch extracellular domain (55).
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Figure 1.2 Notch signaling pathway.
Binding of Notch ligands, including Jagged-1, permits cleavage of Notch receptor first by
ADAM10, and then by the gamma secretase complex. The liberated Notch intracellular
domain (NICD) then translocates to the nucleus and activates transcription.

Cleavage of Notch extracellular domain is followed by cleavage of the Notch
intracellular domain (NICD) by the gamma secretase complex. The liberated NICD then
translocates to the nucleus where it binds and activates the transcription factor
recombinant signal binding protein for immunoglobulin kappa J region (RBP-Jκ).
Targets of the Notch signaling pathway include Hes and Hey family members, as well as
proteins involved in cell growth including cyclin D1 and c-myc (56,57). Inhibition of
Notch pathway activators, including Notch ligands and alpha secretases such as
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ADAM10 and ADAM17, is a potential method of suppressing Notch pathway activity in
cancer. The Notch ligands Jagged-1 and Jagged-2 are overexpressed in breast cancer
tissue compared to surrounding normal breast tissue, and high tumor expression of either
ligand is associated with reduced survival in breast cancer patients (58–62). ADAM10
and ADAM17 are also critically involved in Notch pathway activation. ADAM10
mRNA is overexpressed in breast cancer tissue compared to normal breast tissue, and
high expression of ADAM10 inversely correlates with survival in breast cancer patients
(63–65). ADAM17 expression is directly correlated with tumor grade and inversely
associated with survival in breast cancer patients (66). Collectively, the results indicate
that targeting Notch ligands and alpha secretases is clinically relevant in breast cancer
patients.
Efforts to inhibit Notch signaling in cancer patients have focused primarily on
development of gamma secretase inhibitors (GSIs). GSIs have effectively reduced tumor
size in animal models, however, use of GSIs in humans is associated with unacceptable
gastrointestinal side effects including diarrhea (49,67). Inhibition of ADAM and related
matrix metalloprotease protein families has been attempted in the past for treatment of
rheumatoid arthritis (68). These attempts, however, were accompanied by
musculoskeletal side effects which limited efficacy of clinical testing (68). Recent
approaches to inhibiting ADAM10 and ADAM17 in cancer include development of a
monoclonal antibody (69), as well as specific low-molecular weight inhibitors including
INCB3619 and INCB7839 (70–73). Interestingly, a clinical trial of INCB7839 combined
with trastuzumab in HER2+ breast cancer patients seemed to yield positive results
without apparent toxicity (73), although further clinical trials are required to fully
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establish the safety and efficacy of this drug. While use of dietary agents to modulate
ADAM family members has been reported in models of Alzheimer’s disease (74),
inhibition of ADAMs with dietary agents in cancer has not been explored.
In the current study, we hypothesized that DATS inhibits Notch signaling pathway
in breast cancer cells. We first utilize a trypan blue assay to show that DATS inhibits
viability of MDA-MB-231 and MCF-7 breast cancer cells, and the Harvey-ras (H-Ras)
transformed MCF10A-H-Ras breast epithelial cell line. Viability of MCF-12A cells, a
model of normal breast epithelial tissue, following DATS treatment was affected to a
lesser extent compared to breast cancer cells. In addition, DATS blocks colony
formation in MDA-MB-231 and MCF-7 breast cancer cells in an in vitro clonogenic
assay. We also report a novel mechanism of action of DATS by inhibiting protein
expression of ADAM10 and ADAM17 in cultured breast cancer cells. The Notch ligands
Jagged-1 and Jagged-2 are inhibited by DATS treatment, suggesting that DATS may play
a role in modulation of Notch signaling pathway in breast cancer cells.
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CHAPTER 2. MODULATION OF NOTCH SIGNALING PATHWAY BY DIETARY
AGENTS

2.1

Introduction

Notch was first identified in Drosophila by observation of a notched wing
phenotype in mutation-bearing flies (75). Years later, an activating mutation in the Notch
receptor was discovered in T-cell acute lymphoblastic leukemia, implicating the pathway
in cancer initiation (76–78). Since then, dysfunctional Notch signaling has been
identified in a number of other cancer types including breast, lung, and glioma, among
others (49,50).
Downstream targets of Notch signaling, while context-dependent, include proteins
related to cell cycle progression, cell survival, and cell fate decisions. These proteins are
particularly crucial for proper embryonic development in mammals, although the
pathway maintains relevance in adults as well. In adults, Notch maintains tissue-specific
stem cell populations, such as those found in the intestinal crypts, through the process of
self-renewal (54,79). By extension, aberrantly activated Notch maintains the CSC
population in transformed cells (80). Notch-mediated CSC maintenance, combined with
the pathway’s role in promoting cell survival and proliferation, helps establish a rationale
for targeting Notch in cancer treatment. Further strengthening the argument for targeting
Notch in cancer is an array of clinical data in which expression of Notch pathway
components is inversely associated with survival and directly associated with metastasis
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(50,60). In accordance with this observation, several therapeutic agents have been
designed to specifically target and inhibit Notch, although the safety and efficacy of these
agents are still being tested (49,81,82). As an alternative to small molecules or biologics,
several researchers have focused their attention on the identification of novel dietary or
natural agents which modulate Notch. This review will critically examine the efficacy of
several dietary and natural agents in modulation of the Notch signaling pathway in the
context of cancer.

2.2

Notch Signaling

The Notch signaling pathway plays a role in development of cancer and in
regulation of CSCs. Below we describe the Notch signaling pathway, and discuss its
relevance to cancer.

2.2.1

Notch Signaling Pathway

The Notch signaling pathway has several levels of regulation to fine-tune pathway
activation (Figure 2.1). In the canonical pathway, a membrane-bound Notch ligand binds
and activates the Notch receptor on a neighboring cell. This ligand binding event leads to
subsequent cleavage of the Notch receptor and liberation of the NICD. NICD, the
pathway effector, translocates to the nucleus following cleavage, where it binds RBP-Jκ
to activate transcription. Within each step of this process, layers of regulation take place
to ensure the correct level of signaling is achieved, as discussed below.
Five single-pass transmembrane Notch ligands (DLL-1, -3, and -4, Jagged-1, and -2)
have been identified in mammals. The mechanism by which Notch ligands activate
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Figure 2.1 Effect of dietary agents on Notch pathway in cancer cells in vitro.
Notch ligands, including Jagged-1, bind to and permit cleavage of the Notch receptor.
Notch extracellular domain is cleaved first by ADAM10; Notch intracellular domain
(NICD) is then cleaved by gamma secretase. NICD activates transcription in the nucleus.
Dietary agents that modulate Notch in cancer cells in vitro are listed.

receptors is referred to as trans activation, that is, the ligand present on one cell activates
a receptor on a neighboring cell (83). Notch ligands that are co-expressed in the same
cell as the Notch receptor display cis-inhibition, and block Notch pathway activation (84).
The mechanism by which this occurs may involve spatial and temporal restrictions in
ligand or receptor expression, as well as ligand-to-receptor ratios (83,84). Recent work
has identified the possibility of a shifting sender/receiver cell phenotype based on
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expression of specific Notch ligands (Delta versus Jagged) and driven in part by the
activity of Fringe (85).
Notch ligands activate one of four membrane-bound Notch receptors (Notch-1, -2,
-3, -4). Following transcription and translation of the full-length Notch receptor, the
polypeptide is cleaved (S1 cleavage) by furin-like proteases to yield the mature form of
the receptor which embeds in the plasma membrane. The receptor itself is categorized
into discrete domains. The extracellular domain is comprised of 29-36 tandem epidermal
growth factor (EGF)-like repeats, of which 11-12 are required for signal activation and
24-29 are associated with cis-inhibition (54). The extracellular domain also homes a
negative regulatory region which blocks pathway activation in the absence of Notch
ligands. The EGF repeats are frequently modified with sugar groups, which may play a
role in specific ligand binding and overall pathway activity (83,85). The intracellular
Notch domain is comprised of an RBP-Jκ association molecule domain, 7 ankyrin repeats,
and a C-terminal PEST domain (rich in amino acids proline, glutamic acid, serine, and
threonine). The PEST domain is subject to phosphorylation and ubiquitination events
which determine the rate at which the Notch intracellular domain is degraded (83).
Contact between a ligand and receptor induces S2 cleavage of Notch, liberating the
Notch extracellular domain which is endocytosed into the ligand-expressing cell (54). S2
cleavage is performed by the alpha secretase ADAM10. The S2 cleavage site is
embedded in Notch’s negative regulatory region, suggesting that binding of a Notch
ligand must induce a conformational change in Notch that permits access of the S2 site to
ADAM10 (54). Notch can also be activated by ligand-independent mechanisms (86).
For example, in the absence of a trans ligand, the intact Notch receptor is internalized for
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transport to the lysosome for degradation. The Notch receptor may be “accidentally”
cleaved from endocytic vesicles prior to arrival at the lysosome and degradation, thereby
activating Notch signaling in the absence of a Notch ligand (86). Additionally, Notch
receptors can be cell-autonomously activated in the absence of inhibitory cis ligands (86).
Finally, deletions in the negative regulatory region of the Notch receptor, such as those
found in T-cell acute lymphoblastic leukemia (T-ALL), permit ligand-independent
pathway activation (78). ADAM17 preferentially performs S2 cleavage under such
ligand-independent circumstances (87).
Shedding of the Notch extracellular domain by ADAM10 or ADAM17 yields a
membrane-tethered Notch intracellular fragment called Notch extracellular truncation.
This shedding event permits S3/S4 cleavage of Notch extracellular truncation, which is
performed by the gamma secretase complex. Presenilin is the active component of the
gamma secretase complex, and is associated with other core proteins including nicastrin,
anterior pharynx defective-1, and presenilin enhancer-2 (88). Gamma secretase cleavage
liberates the intracellular fragment NICD.
NICD translocates to the nucleus where it binds RBP-Jκ, a DNA-binding protein.
Binding of NICD to RBP-Jκ induces recruitment of mastermind-like and the
transcriptional activation complex while simultaneously displacing transcriptional
repressors. The result is conversion of RBP-Jκ from a transcriptional repressor to a
transcriptional activator. Expression of Notch target genes is highly context-dependent
and varies considerably between different cell types. Classic Notch downstream targets
include the basic helix-loop-helix transcriptional repressors Hes and Hey family members.
Some other examples of Notch targets include proteins involved in cell cycle progression
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such as cyclin D1, those involved in cell survival such as c-myc, and several others
(50,89).
Members of the Hes and Hey family of proteins are frequently used as a measure of
pathway activation given their ubiquitous activation following Notch stimulation. Hes
proteins may, however, play a role in Notch pathway inhibition, creating a negative
feedback loop. Evidence of this feedback has been noted in neural development,
embryonic stem cells, and recently in breast cancer (90–92). Alternatively, RBP-Jκ
reporter activity and NICD levels have also been used as indicators of pathway activation,
although this latter method depends on detection of what is, in some contexts, a shortlived protein (80).

2.2.2

Cross Talk

Notch signaling cross talks with several pathways including Ras, Wnt, nuclear
factor kappa B (NF-κB), Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) signaling and others (80). Simultaneous overexpression of Ras and Notch1 induced malignant transformation of HMLE breast epithelial cells, while
overexpression of either of these two genes alone did not result in transformation,
suggesting a cooperative relationship between the pathways (58). The Notch ligand
Jagged-1 is a transcriptional target of Wnt signaling pathway (93). In addition, β-catenin,
a component of Wnt signaling pathway, can directly bind NICD in HEK293 cells; and
overexpression of β-catenin increases Hes-1 reporter activity in mouse embryonic
fibroblasts (94). These data suggest that Wnt activation can augment Notch pathway
activity. Below we focus on cross talk between Notch and NF-κB as well as Notch and
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JAK/STAT, as these are immediately relevant to our discussion of modulation of Notch
with dietary agents in cancer cells.
An elaborate review of cross talk between Notch and NF-κB in the context of
cancer is available (95), and we will address recent discoveries in the field. Prior to
pathway stimulation, NF-κB is sequestered in the cytosol by inhibitor of κB (IκB).
Pathway stimulation activates IκB kinase (IKK), composed of IKKα, IKKβ, and IKKγ.
Activated IKK phosphorylates IκB, leading to its ubiquitination and subsequent
degradation. Degradation of IκB liberates NF-κB such that it may translocate to the
nucleus where it acts as a transcription factor for downstream targets which promote cell
proliferation, evasion of apoptosis, and an inflammatory response (96,97).
Cross talk between NF-κB and Notch is bidirectional. Inhibition of Notch activates
the IKK complex, thereby deactivating NF-κB (98,99). This relationship may be
explained by an inhibitory effect of Hes-1 on IKK (100). Furthermore, DLL-4 and
mastermind-like-1 enhance NF-κB activation, while Numb-like, a Notch pathway
inhibitor, suppresses the pathway (101–104). Conversely, NF-κB also potently regulates
Notch signaling. Deletion of IKKβ suppresses Hes-1 and Hey-1 expression (105).
Similarly, binding of p65, a protein component of NF-κB, near the Notch-1 promoter
enhances Notch-1 gene expression (106). In basal breast cancer, NF-κB signaling
induced expression of the Notch ligand Jagged-1 (107). NF-κB-mediated induction of
Jagged-1 led to CSC growth (107), indicating a critical role for NF-κB activation in CSC
maintenance. The bi-directional nature of Notch and NF-κB crosstalk suggests that
bioactive dietary agents may be capable of modulating both pathways in tandem.
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JAK/STAT activation is achieved upon ligand binding to membrane-bound JAK
proteins. JAKs then phosphorylate and activate STAT proteins, leading to their nuclear
localization and transcriptional activation of target genes including Bcl-xL and p21 (108).
Similar to NF-κB, Notch signaling overlaps with JAK/STAT signaling in a bidirectional
manner. Hes-1 and Hes-5 both induce activating phosphorylation of STAT3, promoting
pathway activation (109,110). Inhibition of STAT3 reduced gene expression of Notch
pathway components, including Notch-1 and Jagged-1 (106). Similar to NF-κB, dietary
agents may play a direct role in regulation of Notch, or an indirect role through
modulation of JAK/STAT activity.

2.2.3

Notch and Cancer Stem Cells

Of particular interest in cancer biology is the role of Notch in regulation of the CSC
population. CSCs are described as a tumorigenic sub-population of cancer cells
responsible for driving continuous growth of the tumor. Grafting as few as 100 sorted
CSCs into mice leads to robust tumor formation in models of several types of cancer
(111–115). The ability of CSCs to generate tumors in vivo is attributed to their unique
pattern of cell division. Similar to their normal tissue counterparts, CSCs divide
asymmetrically such that one daughter cell self-renews to maintain the CSC population,
while the second daughter cell differentiates into a proliferative, committed progenitor
cell (116). Continued proliferation of progenitor cells permits expansion of a
heterogeneous bulk tumor cell population.
While differentiated bulk tumor cells are often susceptible to treatment, CSCs are
more treatment-resistant. Expression of ATP-Binding Cassette subfamily G-2 and
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ALDH in CSCs contributes to drug efflux and aldehyde detoxification, respectively, in
cell models of breast cancer (117–121). Collective expression of these proteins
contributes to the treatment resistance and longevity of not only CSCs but also normal
tissue stem cells (121,122). The ability of CSCs to resist conventional treatment,
combined with their tumorigenic capacity, permits the regrowth of tumors following
treatment and subsequent patient relapse. Treatment resistance and self-renewal capacity
of these cells also increase their appeal as therapeutic targets, especially for prevention of
cancer metastasis.
There is much debate over the exact origin of CSCs, and two hypotheses currently
rule our understanding (123). The first is that CSCs are genetically mutated versions of
their normal tissue stem cell counterparts. The second view is that CSCs arise from dedifferentiation of cancer cells. There is evidence for both models, suggesting that the two
models are not mutually exclusive. Below we discuss both theories as they relate to
Notch signaling.
The strength of evidence supporting that Notch contributes to normal stem cell and
CSC maintenance is strong, although the precise understanding of how Notch promotes
self-renewal is somewhat incomplete. Recent work demonstrates a critical role of Notch
for CSCs in vitro and in vivo (124). MCF-7 and SUM159 human breast cancer cell lines
were transfected with an RBP-Jκ/Notch reporter construct and Notch activity was
identified by level of green fluorescent protein (GFP) expression (124). Cells with high
GFP expression were identified as Notch+ cells (124). Notch+ cells demonstrated
enhanced sphere forming ability and Notch-4 message expression compared to Notchcells (124). Sorted Notch+ cells also demonstrated enhanced secondary tumor formation
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in non-obese diabetic/severe compromised immunodeficient (NOD/SCID) mice
compared to Notch- counterparts (124). Most interestingly, sorted Notch+ cells were
able to generate Notch+ and Notch- cells in vitro and in vivo, suggesting that Notch+
cells possess stem-cell characteristics (124). Cultured Notch- cells, in comparison,
remained Notch- throughout a 12-week incubation period (124). This study provides
evidence for an overlap between cells which express Notch and the CSC population. In
agreement with this, siRNA against Notch-1 significantly reduced viability of ALDH+
MDA-MB-231 breast cancer cells (125). Notch-1 siRNA also inhibited sphere formation
in breast cancer cells (126). Overexpression of Notch-1 or Notch-2 by plasmid
transfection, conversely, enhanced sphere formation in B16 melanoma cells (127).
Collectively, the evidence suggests a role for Notch in CSC maintenance and selfrenewal and highlights this pathway as a potential therapeutic target in cancer treatment.
The precise mechanism by which Notch signaling maintains CSCs in a state of
pluripotency is incompletely understood. Several genes downstream of Notch have been
implicated for a role in CSC maintenance including Sox9, c-Myc, and Nanog
(57,128,129). Sox9 plays a role in the maintenance of neural stem cells, and combined
with the transcription factor Slug, plays a role in mammary stem cell maintenance
(130,131). Sox9 was identified as a direct Notch target gene, with ten RBP-Jκ binding
sites in its regulatory region (128). c-Myc has also been identified as a key regulator of
stem cell self-renewal and is directly modulated by Notch signaling (57,132). Nanog is
critical for self-renewal of embryonic stem cells (133,134). While an RBP-Jκ binding
site was not identified in Nanog regulatory regions, treatment of MDA-MB-231 breast
cancer cells with Compound E, a selective gamma secretase inhibitor which reduces
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expression of NICD-1 (135), resulted in a 10-fold decrease in Nanog protein (129).
Interestingly, doxycycline-induced overexpression of Nanog in xenografted MCF-7
breast cancer cells resulted in enhanced drug resistance concurrently with increases in
ALDH1 and ATP-Binding Cassette subfamily G-2 gene expression, highlighting the
significance of Nanog expression in breast CSC maintenance (136). Induction of selfrenewal genes by Notch pathway activation is a likely mechanism by which Notch
maintains CSCs.
In accordance with the theory of de-differentiation, there is much support for a
transition from an epithelial to a mesenchymal phenotype in the acquisition of stemness.
Notch induces expression of EMT-activating transcription factors, including Snail, Slug,
Twist, and ZEB (53). Slug suppresses the expression of epithelial markers such as
claudins and occludins, as well as the adhesion protein E-cadherin (137), contributing to
a migratory phenotype. Importantly, normal mammary epithelial cells which are forced
to undergo EMT by ectopic expression of Twist or Snail underwent an expected shift
toward a mesenchymal phenotype as well as enrichment of the CD44high/CD24low cell
population and a significant increase in sphere-forming ability (138). The overlapping
expression of signature EMT transcription factors with characteristics of CSCs suggests a
relationship or overlap between the two cell populations which is modifiable by Notch.
To conclude, Notch signaling plays a key role in maintaining the highly tumorigenic CSC
population. Current evidence suggests that Notch-mediated CSC maintenance occurs
through transcriptional activation of stem cell self-renewal genes and EMT-related
factors.
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2.2.4

Clinical Relevance of Notch in Cancer Development

Clinical data indicate that components of the Notch signaling pathway are
associated with reduced survival in several types of cancer. Expression of the Notch
ligand DLL-4 is inversely associated with overall survival in a meta-analysis of nonsmall cell lung cancer, and high DLL-1 expression is associated with shorter survival in
acute myeloid leukemia (139,140). High levels of DLL-4 in acute myeloid leukemia
served as an independent predictor for relapse-free and overall survival (140). The Notch
ligands Jagged-1 and Jagged-2 were found to be more highly expressed in invasive ductal
carcinoma compared to normal breast tissue (58). Importantly, the Notch ligand Jagged1 was highly expressed in 78% of invasive ductal carcinoma patients, as determined by
immunohistochemistry, highlighting the ubiquitous nature of this target among invasive
breast cancer patients (59). Breast cancer patients with high tumor Jagged-1 expression
had a 42% 5-year survival rate compared to 65% 5-year survival among women with low
tumor Jagged-1 expression (60). The 5-year survival rate further dropped to 32% in
breast cancer patients with tumors which highly expressed both Jagged-1 and Notch-1
(60). In addition, breast cancer patients with high tumor Jagged-1 expression had an
increased likelihood of relapse compared to those with low expression (61). High levels
of Jagged-1 may also correspond with poor prognosis in gastric cancer and possibly in
acute myeloid leukemia, although this observation in acute myeloid leukemia is
controversial (140–142). High expression of Jagged-2, as well, in breast tumors
correlates with poorer overall survival and metastasis-free survival (62). The results
collectively demonstrate induction of Notch ligand expression in several human
malignancies and poor patient outcome associated with this induction.
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Overexpression of Notch receptors is also associated with poor prognosis in cancer
patients. High Notch-1 expression levels serve as independent prognostic predictors in
both gastric cancer and acute myeloid leukemia (140,141). In non-small cell lung cancer,
high tumor Notch-1 and Notch-3 expression was associated with higher levels of lymph
node metastasis, but only Notch-3 expression was inversely correlated with overall
survival (139). Similar to Jagged-1, high expression of Notch-1 and Notch-3 was
associated with reduced probability of survival among breast cancer patients (60). In
non-small cell lung cancer, low levels of Hes-1 were linked with improved survival,
suggesting a protective role of pathway suppression (139). Collectively, these
associations continue to support a rationale for targeting the Notch signaling pathway in
cancer treatment.
Expression of gamma secretase components as well as alpha secretases ADAM10
and ADAM17 is also inversely associated with survival in cancer patients. Expression of
Presenilin-1, the active component of the gamma secretase complex, is inversely
associated with overall survival in gastric cancer (143). High levels of ADAM10 are
associated with reduced overall survival and high aggressiveness in nasopharyngeal
carcinoma (144). In triple-negative and HER2+ breast cancer patients, high expression of
ADAM10 is associated with poor survival (64,65). Expression of ADAM17 is also
inversely associated with patient survival in breast cancer and clear cell renal cell
carcinoma (66,145,146).
Several approaches to inhibiting Notch signaling in cancer are undergoing active
research. Use of GSIs to limit Notch pathway activation has gained a great deal of
attention in the field, and monoclonal antibodies against Notch pathway components are
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also under investigation. These strategies have been reviewed (49,81,82). GSI use in
cancer is associated with undesirable side effects, including diarrhea, nausea, and
vomiting (147). A recent clinical trial shows that administration of the GSI MK0752 and
docetaxel to patients with metastatic or locally advanced breast cancer may reduce the
breast CSC population, however, the drug combination resulted in diarrhea, pneumonitis,
and altered liver function tests (148). More recently, inhibition of alpha secretases
including ADAM10 and ADAM17 has gained attention for Notch inhibition in cancer.
ADAM and matrix metalloprotease inhibitors have been used for treatment of
rheumatoid arthritis, although the occurrence of musculoskeletal side effects from this
treatment limited drug efficacy (68). Specific low-molecular weight ADAM inhibitors,
as well as an anti-ADAM10 antibody, are undergoing pre-clinical and clinical testing for
efficacy in cancer treatment (69–73). Combination of trastuzumab and the ADAM
inhibitor INCB7839 in HER2+ breast cancer patients reduces shedding of the HER2
extracellular domain, although a prolonged trial is needed to determine the safety and
efficacy of INCB7839 (73). Modulation of ADAM10 has also been achieved with
dietary agents including curcumin analogs in HEK293 cells (149).
Given the crucial role of Notch signaling in normal tissue, an ideal therapeutic
agent would specifically target Notch signaling in cancer cells while leaving Notch in
normal tissue unaffected. Use of diet-derived agents either alone or in combination with
current chemotherapeutics may be a possible route for targeting Notch in cancer cells
with minimal toxicity to surrounding healthy tissue (150).
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2.3

Modulation of Notch Pathway by Dietary Agents

The appeal of diet-derived solutions for treatment or prevention of cancer
originated from epidemiological data suggesting that select populations may have a lower
cancer risk based on their dietary patterns. Correlations have been identified between the
Mediterranean diet, for example, and reduced cancer risk (151). Reductionist
examinations of diet patterns indicate that specific foods and molecules underlie the
reduced risk of disease development, suggesting that these molecules could be used in
chemopreventive or treatment-focused models.

2.3.1

Curcumin

Curcumin and its analogs reduced expression of Notch pathway components
including Notch-1, Jagged-1, components of the gamma secretase complex, and Notch
downstream targets in several cancer cell models including colon and pancreatic cancer,
among others (Figure 2.1, Table 2.1) (152–161). Of important note, curcumin analogs or
alternate methods of curcumin delivery are desirable given the low bioavailability of
curcumin from its dietary source, turmeric (161,162). In a xenograft model of colon
cancer, oral administration of the turmeric/phospholipid drug Meriva inhibited expression
of NICD-1 in the tumor tissue (159) (Table 2.2). Combining Meriva and oxaliplatin had
a stronger inhibitory effect on tumor volume, expression of Ki-67, NICD-1, and cleaved
caspase 3 compared to Meriva or oxaliplatin alone (159). The inhibitory effect of
curcumin on Notch signaling components was further underscored in an in vitro model of
colorectal cancer in which curcumin attenuated an oxaliplatin-induced increase in NICD1 expression (159). In addition, oral administration of 5 mg/kg/d of CDF, a difluorinated
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Table 2.1 Effect of dietary agents on Notch pathway components in vitro by cancer type.
*indicates use of dietary analog, #indicates alternate delivery method e.g. nanoparticle.

DATS
EGCG

Genistein

PEITC
Resveratrol

Retinoic Acid

Sulforaphane

Vitamin D

Hes-1

↓

↓

↓

Hey-1

Jagged-1

↓
↓
↓
↓
↓
↓
↓
↓
↑
↓
↓
↓
↓
↓
↓
↓

Suppressed
Notch-3

Cancer Type
Cholangiocarcinoma
Colorectal*, #
Esophageal
Lymphoma
Oral
Osteosarcoma
Pancreatic
Osteosarcoma
Colorectal
Head and Neck
Neuroblastoma
Breast
Neuroblastoma
Pancreatic
Prostate
Pancreatic
Prostate
Breast
Cervical
Carcinoids
Glioblastoma
Medulloblastoma
Ovarian
T-ALL
Thyroid
Breast
Glioblastoma
Neuroblastoma*
Ovarian
Pancreatic*
Pancreatic
Prostate
Prostate
Breast*

Notch-2

Dietary Agent
Curcumin

↓

Induced
Notch-1

↑

↓

↓
↓
↓
↓
↓

↓
↓

↓
↓
↓
↓

↓
↓
↑
↑
↑
↓
↑
↓
↓
↓
↓
↓
↓
↑
↓
↓

↓
↓

↓

↑
↓

↓

↓
↓

↑
↓

↓
↓

↑

↑
↓

↓
↓

↑

↑

References
(157)
(159–161)
(155)
(153)
(162)
(156)
(152,158)
(156)
(163)
(164)
(165)
(166)
(167)
(168–172)
(173)
(174)
(175)
(176)
(177)
(178)
(179)
(180)
(181)
(182)
(183)
(184)
(185)
(186)
(187)
(188)
(189)
(190)
(191)
(92)
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curcumin analog, effectively reduced Notch-1 protein and Notch-1 mRNA expression in
a model of MiaPaCa2-xenograft SCID mice (Table 2.2) (158). CDF decreased
expression of Notch-1 protein in colon cancer cells and increased expression of the Notch
inhibitor miR-34a (161,192). The effect of curcumin on miR-34a is controversial,
however, as miR-34a was inhibited by the natural form of curcumin in esophageal cancer
cells (155). Notch-1 was suppressed by curcumin in esophageal cancer cells (155),
suggesting additional mechanisms by which curcumin targets Notch signaling.
Collectively, the results support use of curcumin as a Notch inhibitor across several
cancer types, either alone or in combination with anticancer drugs.
Recent research indicates that increased expression or activity of ADAM10 is
desirable for blocking development or progression of Alzheimer’s disease (74).
Increased ADAM10 activity in models of cancer, however, may enhance cleavage and
activation of Notch (193). In HEK293 cells, curcumin did not affect ADAM10
expression, however, isoleucine-, phenylalanine-, and valine-curcumin conjugates
increased ADAM10 expression (149). The role of curcumin in modulation of ADAM10
specifically in cancer cells has not been researched.
Curcumin-induced alterations in Notch signaling mediate changes in downstream
signaling pathways including NF-κB and JAK/STAT. Treatment of pancreatic and oral
cancer cells with curcumin reduced NF-κB DNA-binding (152,154). NF-κB DNAbinding activity was reduced by curcumin treatment in pancreatic cancer cells in a Notchdependent manner (152). NF-κB DNA-binding was also impaired by curcumin treatment
in a model of oral carcinoma, however, this model did not establish whether NF-κB
inhibition was Notch-dependent (154). Curcumin also induced expression of the
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Table 2.2 Effect of dietary agents on Notch pathway components in vivo by cancer type.
*indicates use of dietary analog, #indicates alternate delivery method e.g. nanoparticle.
Dietary Agent
Curcumin

Cancer Type
Colorectal#

Pancreatic

Genistein

Breast
Prostate

Honokiol

Colorectal

Sulforaphane
Vitamin D

Prostate
Ovarian*

Observations
↓ NICD-1, Ki67
↑ cleaved Caspase 3
tumor volume; additive effect on
↓
tumor volume with oxaliplatin
Notch-1, Epithelial Cell Adhesion
↓
Molecule, Nanog
↓ tumor volume
↓ Notch-1, Cyclin D1
↓ Notch-1, p-Akt, FoxM1
↓ tumor volume
NICD-1, Jagged-1, Hes-1,
↓
Presenilin-1, Nicastrin
↓ tumor volume
↑ NICD-2
↓ Notch signaling pathway
↑ DNA fragmentation
↓ tumor volume

References
(159)

(158)

(194)
(173)
(195)

(190)
(196)

cytosolic NF-κB inhibitor IκBα in lymphoma cells, suggesting NF-κB pathway
deactivation (153). The putative NF-κB deactivation downstream of Notch is one
mechanism by which curcumin may diminish proliferation and enhances apoptosis in
cancer cells.
In addition to NF-κB, curcumin inhibits the JAK/STAT signaling pathway.
Nanoparticle-delivered curcumin treatment of glioblastoma and medulloblastoma cell
lines reduced activating STAT3 phosphorylation at tyrosine 705 (162). The same effect
was observed in isolated ALDH+/CD133+ colon CSCs following treatment with the
curcumin analog FLLL32 (160). Given the roles of both NF-κB and JAK/STAT in
cancer progression, targeting these pathways either directly or secondary to Notch
inhibition with dietary agents is likely to impair cancer cell survival.
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Curcumin reduces invasiveness and CSC properties in several cell models of cancer.
Curcumin treatment inhibited invasion of oral carcinoma and osteosarcoma cells, and in
osteosarcoma this effect was reversed by ectopic Notch-1 expression (154,156). Matrix
metalloprotease-9 was down-regulated by curcumin treatment in osteosarcoma, oral
carcinoma, and pancreatic cancer cells (154,156,158). Curcumin and its analogs inhibit
the size and number of tumorspheres formed in colon, pancreatic, and esophageal cancer
cells, suggesting inhibition of the CSC population by curcumin (155,158–160).
Oxaliplatin treatment of colorectal cancer cells enhanced ALDH activity and this effect
was countered by curcumin (159). Similarly, nanoparticle-delivered curcumin reduced
the CD133+ CSC fraction in medulloblastoma and glioblastoma cell lines (162).
Collectively, the results suggest that curcumin may have clinical application in
preventing invasion and metastasis of primary tumors, as well as tumor recurrence related
to CSCs.

2.3.2

Genistein

Studies examining the efficacy of genistein, an isoflavone found in soy,
demonstrate consistent Notch inhibition across multiple types of cancer (Figure 2.1,
Table 2.1). Use of genistein to target Notch has been particularly well studied in
pancreatic cancer cell lines, although cell models of neuroblastoma, prostate, and breast
cancer have also been reported. Treatment with genistein up-regulated the Notch
inhibitor miR-34a in pancreatic cancer cells and suppressed Notch-1 (168). Both Notch1 mRNA and protein (166–173) are suppressed by genistein treatment in vitro,
suggesting that genistein plays a role in transcriptional and post-transcriptional regulation
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of Notch-1. The Notch downstream target Hes-1 is also suppressed by genistein in
cultured pancreatic cancer and neuroblastoma cell lines (167,169,170). Importantly,
Notch-1 siRNA and over-expression of Notch-1 by viral transduction respectively
augmented and attenuated the effects of genistein on growth of cultured pancreatic and
prostate cancer cell lines, underscoring the critical role of Notch signaling in cell viability
(169,170,173). In a xenograft model of prostate cancer utilizing SCID mice, genistein
administered either through dietary incorporation or by gavage reduced Notch-1,
phosphorylated Akt, and FoxM1 proteins, and reduced tumor growth relative to untreated
animals (Table 2.2) (173). The results support use of genistein as an anticancer agent and
are consistent with the in vitro data for its inhibitory role against Notch and overall cell
survival.
One model examining the efficacy of genistein in breast cancer prevention
followed female rats fed lifelong diets containing one of the following as the sole protein
source: soy protein isolate, casein, or casein supplemented with genistein (Table 2.2)
(194). Mammary epithelial cells, which give rise to mammary tumors, isolated from rats
upon sacrifice at post-natal day 50 fed either the soy protein isolate or the supplemented
diet had reduced expression of Notch-2 mRNA compared to rats fed casein alone. The
supplemented diet had no effect on Hes-1 mRNA expression, but cyclin D1 protein
staining was induced relative to casein alone. Interestingly, soy protein isolate-fed rats
exhibited higher levels of Hes-1 mRNA compared to casein-fed rats, which may indicate
Notch activation via a different Notch receptor (194). The results indicate that orally
administered genistein inhibits Notch-2 mRNA in cancer-free rats, although it cannot be
determined if this inhibitory effect translates to a chemopreventive effect.
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Similar to curcumin, genistein treatment reduced NF-κB binding activity in
pancreatic cancer cells (169–171). Notch-1 overexpressing AsPC-1 pancreatic cancer
cells had increased p65 expression compared to control-transfected cells, and this
increase was attenuated by genistein in a dose-dependent manner (172). A decrease in
p65 protein was also observed in SH-SY5Y and SK-N-BE2 neuroblastoma cells
following genistein treatment (167). The observed decrease in Notch and NF-κB
expression occurred concomitantly with cell cycle arrest, apoptosis, and reduced
proliferation in cancer cells (167,169–172).
Genistein blocks EMT-related proteins, including ZEB1, ZEB2, Snail2, and
Vimentin, and induces E-cadherin in pancreatic cancer cells (172). Decreased migration
was observed in an in vitro wound healing assay in pancreatic cancer cells after genistein
treatment, suggesting that genistein reverses EMT (172). Genistein also inhibits matrix
metalloproteases-2 and -9, epidermal growth factor receptor (EGFR), vascular
endothelial growth factor, and basic-fibroblast growth factor in a neuroblastoma cell
model (167). In AsPC-1 pancreatic cancer cells, overexpression of Notch-1 increased
sphere formation; treatment with genistein suppressed sphere formation in both controland Notch-transfected cells, suggesting that genistein can attenuate Notch-1 mediated
sphere formation (172). The results indicate that genistein can reverse EMT and inhibit
CSCs in vitro.

2.3.3

EGCG and Tea Polyphenols

Epigallocatechin-3-gallate (EGCG) and green tea extract modulate expression of
Notch pathway components in vitro (Table 2.1). EGCG inhibited Notch-1 in SK-N-BE2
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and SH-SY5Y neuroblastoma cell lines (165). Similarly, EGCG suppressed Notch-1 in
CSCs isolated from head and neck squamous cell carcinoma surgical specimens and
Notch-2 in cultured colon cancer cell lines (163,164). Pre-treatment of head and neck
CSCs with cisplatin (10 μM) either alone or in combination with EGCG (5 μM) prior to
grafting resulted in decreased tumor growth in both models, and the effect was strongest
with co-treatment (164). EGCG treatment nearly ablated Hes-1 gene expression in colon
cancer cell lines, suggesting pathway deactivation (163). Oral administration of EGCG
to HT-29 colon cancer cell-xenograft nude mice decreased tumor growth at all doses (5,
10, or 20 mg/kg/d), in a dose-independent manner (163). Theaflavin-3,3’-digallate (TF3)
is an analog of EGCG generated from its polymerization and oxidation and is shown to
have bioactivity against ovarian cancer cells (197). TF3 treatment of OVCAR-3 cells
reduced expression of NICD-1 (197).
EGCG treatment induced Notch-4 expression in squamous cell carcinoma of the
tongue cell lines SCC-25 and Cal-27, although this effect varied by EGCG incubation
time and cell line (198). While EGCG and green tea extract both induced cell cycle
arrest in SCC-25 and Cal-27 cells, it is unclear if this effect was mediated by Notch
signaling or by some other mechanism (198). In neuroblastoma N2A cells transfected
with mutated amyloid precursor protein, EGCG induced expression of the active
fragment of ADAM10 protein, which corresponded with increased levels of soluble
amyloid precursor protein (199). Further research on the role of EGCG in ADAM10
modulation in several malignancies is needed.
EGCG and its related compounds modulate Notch-related pathways and processes,
including angiogenesis, EMT, and maintenance of a CSC phenotype. TF3 inhibited c-
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Myc, hypoxia-inducible factor 1α, and vascular endothelial growth factor in ovarian
cancer cells (197). Inhibition of c-Myc, hypoxia-inducible factor 1α, and vascular
endothelial growth factor by TF3 was reversed by ectopic expression of NICD-1,
suggesting a critical role of Notch pathway in angiogenesis that is modifiable by TF3
(197). EGCG treatment of neuroblastoma cell lines induced expression of E-cadherin,
suggesting a shift towards an epithelial cell phenotype (165). Proteins which contribute
to cancer cell invasiveness such as matrix metalloproteases-2 and -9 were also suppressed
following EGCG treatment (165). EGCG-mediated Notch inhibition reduced sphere
formation in head and neck carcinoma cells, and this effect was augmented by the
addition of cisplatin (164), suggesting a beneficial role of EGCG in addition to
conventional anticancer drugs. Taken together, the data support inhibition of Notch
receptors and activity by EGCG in vitro, as well as a role for EGCG in reducing markers
of an aggressive cancer phenotype.

2.3.4

Resveratrol

Studies of resveratrol, the stilbene found in the skins of grapes, blueberries, and
peanuts, underscore the context-dependent nature of Notch signaling as both oncogenic
and tumor suppressive (Table 2.1). Several studies examining the role of resveratrol on
modulation of Notch signaling show a dichotomy of evidence regarding the specific
effect of resveratrol on Notch pathway components and the biological significance of
their modulation.
Accumulating evidence suggests that select cancer types, including neuroendocrine
tumors such as thyroid cancers and carcinoids, rely on Notch activation for tumor
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suppression (200). Resveratrol induced Notch-1 and Notch-2 expression in
neuroendocrine tumors (178,183,201). Resveratrol reduced tumor volume in xenograft
animal models using pulmonary carcinoid or anaplastic thyroid carcinoma cells (178,201).
Daily injections of 5 mg/kg/d or 2 mg/animal/d decreased tumor growth in NCI-H727
and HTh7 xenograft tumors, respectively (178,201). A similar effect was observed when
resveratrol was administered to NCI-H727 nude mice by oral gavage (201).
Resveratrol activates Notch in glioblastoma and medulloblastoma (179,180). The
biological significance of Notch activity in brain tumors is currently unclear and may be
dependent on specific receptor activation, although some research suggests that Notch
activation has a tumor suppressive function (202). Resveratrol treatment reduces
medulloblastoma cell survival (180). However, addition of L-685,458 (a GSI, hereafter
referred to as GSI-L) did not reduce cell survival, suggesting that induction of Notch by
resveratrol does not play a causal role in reducing medulloblastoma cell viability (180).
In glioblastoma cells, however, the GSI MRK-003 reduced resveratrol-mediated
inhibition of proliferation, supporting a tumor suppressive role of Notch in glioblastoma
(179).
Resveratrol suppresses Notch in cell models of T-cell acute lymphoblastic
leukemia, cervical, ovarian, and breast cancer (176,177,181,182). In ovarian and cervical
cancer, however, addition of GSI-L caused a decrease in Hes-1 protein expression
without altering viability, suggesting that Notch inhibition is dispensable to cancer cell
death (177,181). In highly invasive MCFCA1a and lowly invasive MCFCA1h breast
cancer cells, resveratrol enhanced binding of DNA methyl transferase-3B to the
mastermind-like enhancer and induced mastermind-like-2 enhancer methylation and gene

38
silencing (176). Resveratrol reduced expression of Hes-1 and Hey-1 in MCFCA1a and
MCFCA1h cells (176), suggesting pathway deactivation. Collectively, these studies
continue to highlight the context-dependent nature of Notch signaling by resveratrol and
the differential effect of pathway activation by cell type.

2.3.5 Retinoic Acid
Retinoic acid and its related compounds, collectively referred to as retinoids, inhibit
Notch expression and signaling in cultured cancer cells (Figure 2.1, Table 2.1). All-trans
retinoic acid (ATRA) reduced Notch-1 expression in glioblastoma and ovarian cancer,
and NICD-1 expression was blocked in the glioblastoma model, suggesting pathway
deactivation (185,187). In breast cancer, ATRA suppressed Notch-3 protein in MDAMB-231 cells, although was reported to have no effect on Notch-1 or NICD-1 in SKBR3
breast cancer cells (203,204). In contrast, coupling ATRA with somatostatin and
melatonin had an inhibitory effect on Notch-1 and NICD-1 in MCF-7 breast cancer cells
(184). It is unclear whether these differences are cell line-specific, or a result of varying
treatment methods. Treatment with retinoids, including fenretinide (4hydroxy(pheyl)retinamide, 4-HPR) and the adamantyl-substituted compounds (E)-4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (Cl-AHPC) and (E)-3-{2-[3-(1adamantyl)-4-hydroxyphenyl]-5-pyrimidinyl}-2-propenoic acid (AHP3) inhibited Notch1 in neuroblastoma (186) and pancreatic cancer cell lines (188).
ATRA treatment suppressed migration and invasion of ovarian cancer cells in
Transwell chamber assays (187). The retinoid 4-HPR induced E-cadherin, supporting a
role of retinoids in reducing cancer cell migration (186). In contrast, neuroblastoma cells
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treated with 13-cis retinoic acid displayed increased migration compared to untreated
cells in a wound assay (205). The increase in migration was not attenuated by treatment
with the GSI DAPT, suggesting Notch-independent induction of cell migration (205).
Interestingly, treatment of neuroblastoma cells with 13-cis retinoic acid still induced cell
cycle arrest and increased the fraction of Annexin V positive cells (205).
Historically, ATRA has been used as a differentiation-inducing agent (206).
Intuitively, treatment with ATRA reduced sphere size and formation in glioblastoma and
ovarian cancer cells (185,187). Pre-treating glioblastoma and ovarian cancer cells with
ATRA prior to grafting impaired tumor formation in both models, suggesting that ATRA
reduces the tumorigenic capacity of cancer cells (185,187). Furthermore, in a
glioblastoma xenograft model, dissociated ATRA-treated tumors displayed reduced
sphere formation when cultured ex vivo compared to untreated dissociated tumor cells
(185). The retinoids Cl-AHPC and AHP3 also blocked sphere formation in pancreatic
cancer cells (188). ATRA-treated tumor cells in the ovarian cancer model displayed
decreased ALDH-1 expression (187). These data support an anti-CSC role for ATRA in
vitro and in vivo, but the specific role of Notch in ATRA-mediated CSC inhibition is
unclear.

2.3.6 Sulforaphane
Sulforaphane, a dietary agent released from cruciferous vegetables such as broccoli
and broccoli sprouts after processing or chewing, is well studied in the field of cancer.
Sulforaphane down-regulates full-length Notch-1, -2, and -4 proteins in prostate cancer
cells, while up-regulating expression of NICD-1, -2, and -4, suggesting that sulforaphane
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treatment mediates cleavage of Notch receptors (Table 2.1) (190). Hes-1 reporter activity
was induced by sulforaphane in LNCaP and PC-3 cells suggesting pathway activation
(190). In contrast to the NICD-2 induction seen in LNCaP cells treated with
sulforaphane in vitro, tumor tissue from transgenic adenocarcinoma mouse prostate mice
treated with sulforaphane had reduced NICD-2 (190) (Table 2.2). While two studies
have shown that sulforaphane treatment inhibits prostate cancer cell migration and
expression of EMT-related proteins, this effect was Notch-independent (190,191),
suggesting that sulforaphane reduces cell migration through alternative mechanisms.
Sulforaphane inhibited Notch-1 in pancreatic cancer cells, although expression of
other Notch receptors was not described (189). Interestingly, sulforaphane treatment
negated a gemcitabine-induced rise in Notch-1 expression in MiaPaCa2 cells (189). Cotreatment of MiaPaCa2 cells with sulforaphane and gemcitabine more strongly reduced
cell viability compared to use of either agent alone (189). The results suggest that
sulforaphane may enhance the effect of anticancer drugs in pancreatic cancer. In vivo,
sulforaphane effectively inhibited tumor growth in mice when MiaPaCa2 cells were pretreated with the agent before grafting, and when the agent was administered by i.p.
injection following inoculation (189). The combination of sulforaphane and gemcitabine
in vivo, however, reduced animal body weight by approximately 15% (189). Further
studies are required to determine the effect of sulforaphane on Notch in in vivo models of
pancreatic cancer.
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2.3.7

Vitamin D

Results regarding the efficacy of vitamin D as a Notch modulator are mixed. Two
reports show that 1,25-dihydroxyvitamin D3 treatment has no effect on Notch-2, Notch-4,
or Jagged-1 protein expression in a cell model of glioblastoma, or on Notch-1 or Jagged1 in keratinocytes (207,208). In contrast, a similar dose of 1,25-dihydroxyvitamin D3
suppresses Notch target genes in spontaneously immortalized, non-malignant prostate
cells (209). In the MCF10DCIS.com breast cancer cell line, treatment with the Gemini
vitamin D analog BXL0124 blocked Notch-1 activation and expression of Jagged-1, -2,
and DLL-1 (Table 2.1) (92). Interestingly, in the MCF10DCIS.com model, BXL0124
rapidly induced message and protein expression of Hes-1 (92). Knock-down of Hes-1
with siRNA partially reversed the BXL0124-mediated suppression of NICD-1, Jagged-2,
and c-Myc protein. Conversely, Hes-1 overexpression in the absence of BXL0124
suppressed NICD-1, Jagged-2, and c-Myc, suggesting a negative feedback loop in which
Hes-1 inhibits Notch activation (92). Tumor tissue from SKOV-3 xenograft nude mice
i.p. treated with the vitamin D analog MT19c had decreased expression of Notch pathway
components, and increased DNA fragmentation relative to control (Table 2.2) (196).
More data is needed on the role of vitamin D and its analogs on Notch modulation across
several types of cancer.

2.3.8

Other Agents

Treatment of non-small cell lung cancer cells with delta-tocotrienol, a form of
vitamin E, increased miR-34a expression and decreased expression of Notch-1 and
downstream targets (210). Attenuation of Notch signaling by delta-tocotrienol coincided
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with apoptosis and reduced cell migration, and this effect was further enhanced by cotreatment with cisplatin in vitro (211,212).
Honokiol, a traditional Chinese and Japanese herbal therapeutic, inhibited Notch
components, including Notch-1 and -2, Jagged-1, Hes-1, and subunits of the gamma
secretase complex in melanoma and colon cancer cells (195,213,214). In addition, sphere
formation and cell survival were inhibited by honokiol treatment either alone or in
combination with a single dose of ionizing radiation at 5 Gy (195,214). The additive
effect of honokiol and radiation was confirmed in nude mice xenografted with HCT116
cells. Tumor mass along with expression of CSC- and Notch-related proteins were
inhibited by the co-treatment in vivo (Table 2.2) (195), congruent with the reported effect
of honokiol in vitro.
Withaferin A, a lactone found in the leaves of Withania somnifera (Indian Winter
cherry) has been used as part of traditional Indian medicine for several years and inhibits
angiogenesis and cell proliferation (215,216). In breast cancer cells, Withaferin A
treatment suppressed NICD-1 and induced NICD-2 and NICD-4 expression (217). The
net effect was an increase in RBP-Jκ and Hes-1 promoter activity, and reduced migration
and cell viability (217). Knock-down of Notch-2, but not Notch-4, in these experiments
further decreased migration and proliferation in breast cancer cells. Taken together,
activation of Notch-2 by Withaferin A appears unfavorable, but the total effect of
Withaferin A treatment on breast cancer cells is beneficial. In a follow-up study, RNA
interference against Notch-4 did not significantly contribute to Withaferin A-induced
suppression of ALDH1 activity, further identifying Notch-4 induction by Withaferin A as
dispensable for CSC inhibition (218). In ovarian cancer cell lines, Withaferin A has a

43
cell line-dependent effect, with treatment leading to inhibition of NICD-1 and NICD-3 in
SKOV3 and CaOV3 cells, respectively (219). NICD-1 is also inhibited by Withaferin A
in colon cancer cell lines (220). Importantly, viability of the normal colon cell line FHC
was not affected by Withaferin A treatment (220), suggesting low toxicity towards
normal tissue.

2.4

Conclusions

The Notch signaling pathway is one of several pathways which influence
development and progression of cancer. It is particularly important to target Notch, in
part, because of the pathway’s extensive degree of cross-communication with pathways
including Wnt, NF-κB, and JAK/STAT, which collectively confer survival advantages to
cancer cells (221). In addition, Notch activation is critically involved in the maintenance
of highly tumorigenic and treatment-resistant CSCs, which may play a role in tumor
survival and recurrence (82).
The studies detailed throughout this text highlight both the vast progress that has
been made as well as gaps in our current understanding of the relationship between
dietary agents and Notch. It is clear that several dietary agents are capable of achieving
substantial changes in expression of Notch components and pathway activity in vitro,
which may contribute to cancer cell death.
Curcumin and genistein have the highest strength of evidence supporting Notchmediated alterations in cancer cell survival. The indispensable nature of Notch inhibition
by curcumin and genistein, particularly in pancreatic cancer cells, confirms that this
pathway is relevant to tumor progression (152,169,170,173). Most importantly, Notch is
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modifiable by curcumin and genistein in vitro and in vivo in models of pancreatic and
prostate cancer, suggesting that these bioactives may be clinically relevant in the field of
cancer (152,169,173). A major challenge related to curcumin is its relatively poor
bioavailability, although several strategies to improve the bioavailability of curcumin are
undergoing active research (222).
Development of GSIs is a major focus in the field of Notch cancer biology.
Recent research in cancer biology, however, has identified a role of the alpha secretases
ADAM10 and ADAM17 in activation of Notch and alterations to cell migration and
invasion (64,223,224). While each of these genes is required for Notch activation, the
role of dietary agents in modulating ADAM10 or ADAM17 in the context of cancer is
unexplored (225). Discovery of dietary or natural agents which suppress ADAM10 or
ADAM17 specifically in cancer cells will have implications for modulation of not only
Notch signaling, but also EGFR signaling and cell migration (226).
In conclusion, Notch signaling plays a critical role in cancer cell proliferation and
survival. Use of dietary agents such as curcumin and genistein is a novel method of
inhibiting Notch in cancer cells which may result in chemopreventive or anticancer
effects, with low toxicity to normal tissue. Future studies examining the role of dietary
agents in modulation of Notch will further our understanding of Notch biology and
improve cancer prevention and treatment.
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CHAPTER 3. DIALLYL TRISULFIDE MODULATES NOTCH PATHWAY
COMPONENTS IN BREAST CANCER CELLS

3.1

Introduction

Breast cancer is the most frequently diagnosed cancer among US women (1).
Widespread use of mammography has greatly improved early detection of breast
cancer; however, blocking progression to invasive breast cancer remains a clinical
challenge (1,5). Epidemiological data show an inverse relationship between
consumption of Allium vegetables, including garlic and onions, and development of
several types of cancer (17–19). Specifically, a case-control study in France
examining development of breast cancer reported an odds-ratio of 0.25 (95%CI: 0.110.55) among women consuming 11-12 weekly servings of garlic and onions
compared to women consuming fewer than 7 weekly servings (17).
Multiple reports indicate that DATS is a more potent inhibitor of cancer cell
survival compared to its analogs diallyl disulfide or diallyl sulfide (227,228). MCF-7
xenograft mice treated with 5 μmol DATS/kg body weight had significantly smaller
tumors compared to control-treated animals (227). SUM159 xenograft mice treated
with DATS starting on date of implantation had reduced tumor incidence and tumor
weight compared to control-treated animals (34). Tumor tissue from DATS-treated
SUM159 xenograft mice also displayed reduced ALDH1 activity compared to tissue
from untreated mice (175), suggesting DATS targets CSCs in vivo. Importantly,
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DATS treatment does not reduce body weight in xenograft models indicating that
DATS is not toxic to major organs (33,34).
Several mechanisms of action of DATS in cancer cells have been identified in
vitro. Treating cancer cells with DATS mediates production of reactive oxygen
species and induces apoptosis (39). Overexpression of superoxide dismutase or
addition of the antioxidant N-acetylcysteine attenuates the effect of DATS treatment
on apoptosis in cancer cells (39,227). DATS-mediated apoptosis is also attenuated by
the JNK-inhibitor SP600125 (227). Importantly, DATS induces apoptosis in both
triple-negative and ER-positive breast cancer cells (39,227,228). DATS treatment in
breast cancer cells inhibits cell migration, invasion, and mammosphere formation
(46,34). In osteosarcoma cells, DATS suppressed protein expression of the Notch
pathway components Notch-1 and Hes-1, and the Notch downstream target cyclin D1
(47).
Notch signaling is activated in breast cancer cells compared to normal tissue
and plays a role in cell proliferation and differentiation (54,58). Cells with high
levels of active Notch signaling display increased tumorigenic capacity in vivo, and
Notch contributes to CSC maintenance (124). Notch is a juxtacrine signaling
pathway in which membrane-bound Notch ligands activate Notch receptors on
neighboring cells. Notch ligands, including Jagged-1, Jagged-2, DLL-1, -3, and -4,
bind to Notch receptors (Notch-1, -2, -3, -4), inducing a change in receptor
conformation and permitting cleavage of the Notch extracellular domain. Cleavage
of Notch extracellular domain is achieved by ADAM10 in a ligand-dependent fashion.
Cleavage of Notch extracellular domain permits the gamma secretase complex to
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cleave NICD. NICD translocates to the nucleus where it binds RBP-Jκ and recruits
the co-activator mastermind-like, thereby activating transcription. Downstream
targets of the Notch pathway include canonical targets Hes and Hey as well as several
context-dependent targets such as cyclin D1, c-myc, and Nanog (50).
Ligand binding is the first critical step of Notch activation in the canonical
pathway. Importantly, expression of the Notch ligands Jagged-1 and Jagged-2 is
increased in invasive ductal carcinoma compared to benign breast tissue (58). In
addition, overexpression of Jagged-1 in tumor tissue was observed in 78% of patients
with invasive breast cancer, suggesting that Jagged-1 activation is frequently
observed in breast cancer (59). High tumor expression of Jagged-1 and Jagged-2 is
associated with reduced survival and increased probability of relapse (60–62). Notch
ligands therefore represent a potential therapeutic target for Notch inhibition in cancer.
Following Notch ligand binding, cleavage of Notch extracellular domain is
achieved by ADAM proteins. ADAMs are a broad family of proteases responsible
for cleavage of several substrates relevant to cancer progression, including Notch
(225). ADAM proteins are first synthesized as zymogens and are processed by
proprotein convertase-7 and furin at the Golgi to yield active proteases (74). After
processing, active ADAM10 and ADAM17 translocate to the cell membrane where
they cleave the extracellular domains of target substrates, including Notch-1.
ADAM10 constitutively cleaves Notch upon ligand binding, and ADAM17 is capable
of cleaving Notch under ligand-independent conditions (86,87). In addition,
ADAM10 cleaves the cell-cell adhesion protein E-cadherin and HER2, while
ADAM17 is known to cleave pro-tumor necrosis factor-α, among many others (225).
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Expression of tumor ADAM10 and ADAM17 is inversely associated with survival in
several types of cancers, including breast cancer (224).
The Notch signaling pathway has emerged as a therapeutic target in cancer.
The gamma secretase complex is a common target for Notch inhibition in cancer
patients; however use of GSIs in clinical trials has revealed unacceptable
gastrointestinal side effects, nausea, and vomiting (229,230). Development of alpha
secretase inhibitors is underway. Early phase clinical trials of small molecule
inhibitors against ADAM10 and ADAM17 have shown some promise in HER2+
breast cancer patients (231), although previous use of ADAM17 inhibitors for
treatment of rheumatoid arthritis resulted in hepatotoxicity (232).
The hypothesis of the present study is that DATS inhibits Notch signaling
pathway in breast cancer cells. We report a novel mechanism of action of DATS by
targeting alpha secretases and Notch ligands in breast cancer cells. Furthermore, we
show with a clonogenic assay that DATS has a long-lasting effect on breast cancer
cells. We conclude that DATS targets components of the Notch signaling pathway,
including ADAM10, ADAM17, Jagged-1, and Jagged-2 in breast cancer cells.

3.2

Materials and Methods

Cell Culture and Reagents
Human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased
from American Type Culture Collection (ATCC, Manassas VA). MDA-MB-231
cells were derived from a 51 y old female patient with breast adenocarcinoma; the
cells do not express ER, PR, or HER2. MCF-7 cells were derived from a 69 y old
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female patient with breast adenocarcinoma; the cells are ER-positive. MDA-MB-231
cells were cultured in RPMI1640 (Corning, Manassas VA) supplemented with 10%
fetal bovine serum (FBS, Corning) and 1% penicillin/streptomycin antibiotic mixture
(PS, Corning). MCF-7 cells were cultured in Eagle’s Minimum Essential Medium
(MEM, Corning) with 0.01 mg/ml human recombinant insulin (Sigma-Aldrich, St.
Louis MO), 10% FBS, and 1% PS.
MCF10A-H-Ras and MCF-12A cells were kind gifts from Dr. Dorothy
Teegarden and Dr. Ignacio Camarillo, respectively, Purdue University.
Characteristics of the MCF10A-H-Ras cell line are well described in the literature and
have recently been reviewed (233). Briefly, the MCF10A-H-Ras cell line is a
modified version of normal-like MCF-10A breast epithelial cells, with a T24-mutated
Harvey-ras stable gene insertion. These cells are capable of forming ducts in vivo,
and will sometimes progress to invasive ductal carcinoma (233). MCF-12A cells
were derived from a 60 y old Caucasian female with fibrocystic breast disease; the
cells are non-tumorigenic in vivo and serve as a model of normal-like breast tissue
(234). Both cell lines were cultured in Dulbecco’s Modification of Eagle’s Medium
(DMEM)/Ham’s F-12 50/50 Mix (Corning), supplemented with 20 ng/ml human
recombinant EGF (StemCell Technologies, Vancouver BC), 100 ng/ml cholera toxin
(Calbiochem, Billerica MA), 0.01 mg/ml human recombinant insulin, 500 ng/ml
hydrocortisone (Sigma-Aldrich), 5% donor horse serum (Corning), and 1% PS. All
cells were regularly maintained at 37ºC with 5% carbon dioxide.
Diallyl trisulfide (DATS, ≥ 98% purity) was purchased from LKT Laboratories
(St. Paul, MN). DMSO was obtained from Fisher (Pittsburgh, PA), PBS was from
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Corning. Trypan blue was purchased from Mediatech (Manassas, VA) and crystal
violet was purchased from Amresco (Boise, ID). ADAM10 (14194), ADAM17
(6978), Jagged-1 (2155), and Jagged-2 (2210) antibodies were purchased from Cell
Signaling (Danvers, MA) and Actin (A5441) was purchased from Sigma-Aldrich.

Trypan Blue Exclusion Assay
Cells were seeded into 12-well plates at a density of 10,000 cells/well for
MDA-MB-231 cells or 50,000 cells/well for MCF-7, MCF10A-H-Ras, and MCF-12A
cells and allowed to attach for 24 h. Cell culture medium was then replaced with
medium containing DATS (20, 40, 60, 80, 100 μmol/L) or vehicle control (DMSO,
<0.55% v/v). Cells were incubated with DATS for 24 h. Cells were counted in 30
μL trypan blue under a hemocytometer.

Clonogenic Assay
MDA-MB-231 and MCF-7 breast cancer cells (1x106) were plated in 100 mm
plates and allowed to attach for 24 h. Cells were then treated for 24 h with 20, 40, or
60 µmol/L DATS or control (DMSO, <0.4% v/v). After 24 h of DATS treatment,
cells were reseeded into 6 well plates with 300 cells/well and incubated in the absence
of DATS. MDA-MB-231 cells were incubated for 10 d in the absence of DATS, and
MCF-7 cells were incubated 14 d. Growth medium was changed every 3 d. Colonies
were fixed with methanol and stained with 0.5% (w/v) crystal violet prior to counting.
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Western Blotting
Cells were treated with 20, 40, or 60 µmol/L DATS or control (DMSO) for 16
or 24 h. Protein levels were first determined with Bradford reagent. Equal amounts
of protein were then separated on polyacrylamide gels and transferred to PVDF
membranes. Membranes were incubated in primary antibody overnight at 4ºC with
gentle rocking and developed with ECL Prime Detection Reagent (GE Amersham,
Batavia, IL). Band quantification was completed with UN-SCAN-IT software (Silk
Scientific, Orem, UT).

qRT-PCR
Cells were treated with 20, 40, or 60 µmol/L DATS or control (DMSO) for 24 h.
Cellular RNA was isolated using PureLink RNA Mini Kit and PureLink DNase Kit
(Invitrogen, Carlsbad CA), and 2 µg of RNA were converted to cDNA using the
BioRad iScript cDNA Synthesis Kit (BioRad, Hercules, CA). PCR was performed on
80 ng of cDNA using SYBR Green I Master Mix (Roche, Indianapolis, IN) and the
following primers: ADAM10 (forward GTAGTAATCCAAAGTTGCCTCCT,
reverse CAGTTAGCGTCTCATGTGTCC), GAPDH (forward
GGAGCGAGATCCCTCCAAAAT, reverse GGCTCTTCTCATACTTCTCATGG).
Primers were purchased from Integrated DNA Technologies (IDT, Coralville, IA).
PCR was carried out using a LightCycler 96 system (Roche) under the following
parameters: 10 minutes at 95ºC; 45 cycles of 15 seconds at 95ºC, 10 seconds at 60ºC,
and 30 seconds at 72ºC; 10 seconds at 95ºC, 60 seconds at 65ºC, and 1 second at 97ºC.
Message calculations were completed using the 2-ΔΔCt method.
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Statistical Analysis
All statistical analysis was completed using GraphPad Prism 6.0 software (La
Jolla, CA). Trypan blue assay and Western blotting densitometry were analyzed by
one-way ANOVA followed by Dunnett’s multiple comparisons to determine
differences between groups. Clonogenic assay and qRT-PCR data were analyzed by
unpaired t-test to determine differences between groups. P-values < 0.05 were
considered significant.

3.3

Results

Diallyl Trisulfide Reduces Viability of Breast Cancer Cells
We first examined the ability of DATS to inhibit viability of cultured breast
cancer cell lines. Cells were treated with DATS (20, 40, 60, 80, 100 μmol/L) or
control (DMSO) and viability was determined after 24 h using trypan blue exclusion
assay. Treatment with 40 μmol/L DATS reduced cell viability by approximately 53%
in MDA-MB-231 and MCF-7 breast cancer cells, indicating that the IC50 value of
DATS is near 40 μmol/L (Figures 3.1A and 3.1B). Treatment of MCF10A-H-Ras
cells with 40 μmol/L DATS reduced viability by 50% (Figure 3.1C). In contrast,
treatment of the normal-like breast epithelial cell line MCF-12A with 40 μmol/L
DATS reduced viability by only approximately 19% (Figure 3.1D). Furthermore,
treatment of MCF-12A cells with up to 100 μmol/L DATS reduced viability by 46%,
suggesting that the IC50 value of DATS in normal breast tissue is higher than that of
breast cancer cells.
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Figure 3.1 Effect of DATS on viability in breast cancer cells and normal-like breast
epithelial cells.
MDA-MB-231 (A), MCF-7 (B), MCF10A-H-Ras (C), and MCF-12A (D) cells were
treated with increasing doses of DATS for 24 h. Data points, mean (n=2); bars, SEM
of two independent experiments, each performed in triplicate. *, P < 0.05 in
comparison with control-treated cells, by one-way ANOVA followed by Dunnett’s
multiple comparisons test.

Diallyl Trisulfide Inhibits Colony Formation in Human Breast Cancer Cell Lines
We next sought to determine if DATS could inhibit colony formation in breast
cancer cells. Breast cancer cells were treated with DATS (20, 40, 60 μmol/L) or
control for 24 h, reseeded at equal cell densities, and incubated 10-14 d in the absence
of DATS. Treatment with DATS resulted in a dose-dependent decrease in the number
of colonies formed in breast cancer cells (Figure 3.2). Colony formation was
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Figure 3.2 DATS inhibits colony formation in MDA-MB-231 and MCF-7 breast
cancer cells.
Representative wells from MDA-MB-231 (A) and MCF-7 (B) breast cancer cells.
Quantification of colony formation in MDA-MB-231 (C) and MCF-7 (D) breast
cancer cells. Columns, mean (n=2); bars, SEM of two independent experiments, each
performed in triplicate. *, P < 0.05 in comparison with control-treated cells, by
unpaired student’s t-test.
inhibited by approximately 47 and 64% after 60 μmol/L DATS treatment in MDAMB-231 and MCF-7 cells, respectively.

Diallyl Trisulfide Inhibits Alpha Secretase Protein Expression
Alpha secretases, including ADAM10 and ADAM17, are required for cleavage
of membrane-bound proteins relevant to breast cancer progression, including Notch
receptor (226). We tested the ability of DATS to inhibit alpha secretase proteins in
breast cancer cells and H-Ras transformed breast epithelial cells. ADAM10 is first

55

Figure 3.3 Effect of DATS on ADAM10 protein in breast cancer cells at 16 h
treatment.
Representative Western blots of ADAM10 in MDA-MB-231 (A) and MCF-7 (B)
cells after 16 h of DATS treatment. Densitometry analysis of ADAM10 precursor
expression (C) and active ADAM10 expression (D). Columns, mean (n=2); bars,
SEM of two independent experiments. *, P < 0.05 by one-way ANOVA followed by
Dunnett’s multiple comparisons test.

synthesized as a 90 kDa zymogen which is subsequently cleaved by proprotein
convertase-7/furin to yield a 68 kDa active protein (74). DATS treatment downregulated ADAM10 precursor (90 kDa) after 16 h of treatment in MDA-MB-231
breast cancer cells (Figure 3.3A). Active ADAM10 was not affected after 16 h of
DATS treatment (Figure 3.3A and 3.3B). After 24 h of 40 μmol/L DATS treatment,
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Figure 3.4 DATS inhibits ADAM10 precursor and active ADAM10 protein in breast
cancer cells at 24 h treatment.
Representative Western blots of ADAM10 in MDA-MB-231 (A), MCF-7 (B), and
MCF10A-H-Ras cells (C) after 24 h of DATS treatment. Densitometry analysis of
ADAM10 precursor expression (D) and active ADAM10 expression (E). Columns,
mean (n=2); bars, SEM of two independent experiments. *, P < 0.05 by one-way
ANOVA followed by Dunnett’s multiple comparisons test.

ADAM10 precursor was inhibited by approximately 40% in MDA-MB-231 and
MCF-7 breast cancer cells (Figure 3.4A and 3.4B); and active ADAM10 was
suppressed by approximately 80% in MDA-MB-231 and 70% in MCF10A-H-Ras
cells (Figure 3.4A and 3.4C). ADAM17 expression was reduced by DATS in MDAMB-231, MCF-7, and MCF10A-H-Ras cells after 24 h treatment (Figure 3.5).
Collectively, the results support that DATS inhibits alpha secretase expression in
breast cancer cells and H-Ras transformed breast epithelial cells.
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Figure 3.5 DATS inhibits ADAM17 protein in breast cancer cells and H-Ras
transformed breast epithelial cells.
Representative Western blots of ADAM17 in MDA-MB-231 (A), MCF-7 (B), and
MCF10A-H-Ras cells (C) after 24 h of DATS treatment. Densitometry analysis of
ADAM17 expression (D). Columns, mean (n=3 in MDA-MB-231, n=2 in MCF-7
and MCF10A-H-Ras); bars, SEM of two or three independent experiments. *, P <
0.05 by one-way ANOVA followed by Dunnett’s multiple comparisons test.

Effect of DATS on ADAM10 mRNA in Breast Cancer Cells
To elucidate a potential mechanism by which DATS inhibits ADAM10 protein
expression, we performed qRT-PCR on MDA-MB-231 and MCF-7 breast cancer
cells treated with DATS for 24 h. Expression of ADAM10 mRNA following 24 h of
DATS treatment in MDA-MB-231 and MCF-7 breast cancer cells shows a nonstatistically significant inhibitory trend with an increasing dose of DATS (Figure 3.6).
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Figure 3.6 Effect of DATS on ADAM10 mRNA levels in breast cancer cells.
qRT-PCR of ADAM10 in MDA-MB-231 (A) and MCF-7 (B) breast cancer cells.
Columns, mean (n=2); bars, SEM of two independent experiments, each performed in
triplicate. *, P < 0.05 in comparison with control-treated cells, by unpaired student’s
t-test.

Diallyl Trisulfide Inhibits Notch Ligand Expression
Elevated levels of the Notch ligand Jagged-1 are associated with increased
metastatic potential and decreased survival in breast cancer patients (60). We tested
the ability of DATS to inhibit Jagged-1 and Jagged-2 protein expression in breast
cancer cells and H-Ras transformed breast epithelial cells. Twenty-four hours of 40
μmol/L DATS treatment reduced expression of Jagged-1 by approximately 82% in
MCF10A-H-Ras cells and Jagged-2 by 50% in MCF-7 cells, suggesting that DATS
can target Notch ligands in breast cancer cells (Figure 3.7B and 3.7C).

3.4

Discussion

The results of the present study support a role for DATS in inhibition of Notch
signaling pathway in breast cancer cells. We first show that DATS treatment reduces
viability of MDA-MB-231 and MCF-7 breast cancer cells with an IC50 value near 40
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Figure 3.7 DATS inhibits Jagged-1 and Jagged-2 protein in breast cancer cells and HRas transformed breast epithelial cells.
Representative Western blots of Jagged-1and Jagged-2 in MDA-MB-231 (A), MCF-7
(B), and MCF10A-H-Ras (C) cells after 24 h of DATS treatment. Densitometry
analysis of Jagged-1 (D) and Jagged-2 expression (E). Columns, mean (n=2); bars,
SEM of two independent experiments. *, P < 0.05 by one-way ANOVA followed by
Dunnett’s multiple comparisons test.

μmol/L. This is in accordance with other studies that reported an IC50 value for
DATS after 24 h of treatment between 20 and 40 μmol/L in MDA-MB-231 and
MCF-7 cells (190,228). Our work is the first to study the effect of DATS on viability
of MCF10A-H-Ras cells. We show that MCF10A-H-Ras cells are sensitive to DATS
treatment, and have a similar IC50 value to that of breast cancer cells lines.
Importantly, viability of the normal-like breast epithelial cell line MCF-12A was
reduced by DATS to a lesser extent compared to breast cancer cell lines, suggesting
that DATS specifically targets breast cancer cells. This is in agreement with another
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study which showed that DATS did not affect viability of the normal-like breast
epithelial cell line MCF-10A at similar concentrations (39).
Furthermore, we used a clonogenic assay to demonstrate the longevity of
DATS’s effect on cell viability. In this assay, cells were treated with DATS for 24 h,
reseeded at equal cell densities, and incubated for 10-14 days in the absence of further
DATS treatment. The initial DATS treatment reduced colony formation in MDAMB-231 and MCF-7 breast cancer cells by 47 and 64%, respectively. The results
collectively show that DATS reduces the viability and clonal capacity of cancer cells,
and that DATS treatment has a lasting effect on breast cancer cell proliferation.
We report a novel mechanism of DATS by targeting the alpha secretases
ADAM10 and ADAM17 in breast cancer cells. We show that 40 μmol/L DATS
inhibits ADAM10 precursor expression by approximately 40% in MDA-MB-231 and
MCF-7 breast cancer cells within 24 h. Furthermore, 40 μmol/L DATS inhibits
active ADAM10 in MDA-MB-231 cells by 80%. In addition, 40 μmol/L DATS
suppresses ADAM17 by approximately 42% in MDA-MB-231 and 78% in MCF-7
breast cancer cells after 24 h of treatment. ADAM10 plays a critical role in Notch
pathway activation. ADAM10 also cleaves other membrane-bound substrates
relevant to cancer biology, including EGFR ligands pro-EGF and pro-betacellulin, as
well as HER2 (235,236). ADAM10 mRNA expression is higher in breast cancer
tissue compared to surrounding normal tissue (63). In addition, triple-negative and
HER2+ breast cancer patients with high tumor ADAM10 expression demonstrate
poorer survival compared to those with low expression levels (64,65). Interestingly,
it has also been shown that ADAM10 expression is upregulated following
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trastuzumab monotherapy in HER2+ breast cancer patients, suggesting a role for
ADAM10 in trastuzumab resistance (65). The data suggest that ADAM10 expression
is induced in malignant breast tissue, and that overexpression of ADAM10 has
negative consequences for patient survival and possibly drug resistance.
While ADAM10 is constitutively active in the Notch pathway, ADAM17 can
also play a role in Notch cleavage. ADAM17 preferentially cleaves the Notch
receptor in ligand-independent contexts (87). Such contexts are achieved in certain
types of cancer, including T-cell acute lymphoblastic leukemia (78), where mutations
in Notch extracellular domain permit its cleavage in the absence of activating Notch
ligands (237). Notch fusion genes affecting the extracellular domain have been
identified in cultured HC2218, HC1599, and HC1187 breast cancer cell lines (238).
However, a later analysis of malignant breast tissue from Vietnamese and Mexican
patients did not reveal mutations to Notch extracellular domain (239). The
prevalence of Notch extracellular domain mutations in breast cancer is thus
controversial. In breast cancer, ADAM17 protein expression in tumor tissue directly
correlates with tumor grade and inversely correlates with overall survival (66).
Our results are the first to demonstrate that DATS inhibits expression of the
Notch ligands Jagged-1 and Jagged-2 in breast cancer cells. Each of these ligands is
implicated in activating the Notch pathway, and expression of each is inversely
associated with survival in breast cancer (60,62). Mutations in the Notch negative
regulatory region identified in T-cell acute lymphoblastic leukemia permit ligandindependent Notch activation, making Notch ligands in this type of cancer less
clinically relevant (78). In breast cancer, however, mutations in the Notch regulatory
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region have not been conclusively identified (240), indicating that targeting Jagged-1
and Jagged-2 is a clinically meaningful method of suppressing Notch signaling.
These data collectively suggest that targeting Notch ligands as well as alpha
secretases in breast cancer is critically important to prevent liberation of NICD and
subsequent Notch pathway activation. The results of our study suggest Notch
pathway inhibition by DATS. Others have reported an inhibitory effect of DATS on
Notch and Hes-1 in cultured osteosarcoma cells (47).
The safety of DATS has been shown in cell and animal models, and in humans.
Treating the normal breast epithelial MCF-10A cell line with 20 or 40 µmol/L DATS
showed no significant effect on cell viability (39). Micromolar levels of DATS are
potentially achievable in vivo as shown by plasma levels of approximately 30 µmol/L
in rats after receiving a 10 mg injection of DATS administered to the jugular vein
(27). In an MCF-7 xenograft model, mice receiving 5 μmol/L DATS by oral gavage
twice per week displayed a decrease in tumor volume compared to control treated
animals, and no apparent toxicity was reported (227). The safety and efficacy of
DATS for gastric cancer prevention were tested in a clinical intervention study in
China (31). Chinese men and women were instructed to take 200 mg of DATS every
day, in conjunction with 100 µg of selenium every other day. The intervention was
found to have a protective effect against development of gastric cancer in Chinese
men and no harmful side effects were reported, collectively suggesting that DATS is
safe to consume in large doses, and may play a role in gastric cancer prevention (31).
In total, studies in cells, animals, and humans suggest an anticancer effect of DATS
with low toxicity to benign tissue, thereby increasing its appeal for clinical use.
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To conclude, our results have shown that DATS suppresses components of the
Notch signaling pathway which are critically involved in pathway activation in breast
cancer cells. Our results also support a non-toxic effect of DATS in untransformed
breast epithelial cells at similar concentrations, and underscore the long-lasting effect
of DATS treatment on breast cancer cell proliferation. Our work lends support to
further evaluation of DATS as an anticancer or chemopreventive agent.
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CHAPTER 4. CONCLUSIONS

Breast cancer is a major health concern. The incidence of breast cancer over the
past decade has remained stable, underscoring the need for new prevention and
treatment strategies against this disease (1). The classical approach of diagnosing and
treating breast cancer is based on molecular marker expression, e.g. expression of the
estrogen receptor. Treating breast cancer based on molecular subtype is effective;
however, challenges of this approach still arise, including treatment resistance and the
prevalence of triple-negative breast cancer which lacks targeted treatment strategies
(7).
Epidemiological, clinical, translational, and basic research support a role for
Allium vegetables and their constituents as chemopreventive or anticancer agents
(17,34,42,43). DATS has emerged as a highly bioactive component of fresh garlic
capable of inducing cell cycle arrest and apoptosis in several types of cultured cancer
cells, including breast cancer cell lines (42,43,227,241). In the present study, we
report a novel mechanism of action of DATS on Notch pathway components in breast
cancer cells. The rationale behind our investigation is the critical role that Notch
signaling plays in growth and survival of breast cancer cells. Notch is a regulator of
cell proliferation, angiogenesis, EMT, and CSCs (221). In addition, overexpression
of Notch was observed in invasive breast cancer compared to normal breast tissue
(58), establishing a rationale to specifically target Notch in breast cancer cells.
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Several dietary agents have been investigated for their ability to modulate Notch
pathway activity in cultured cancer cells and preclinical animal models. Curcumin
and genistein are potent Notch inhibitors in several types of cancer cells, and
downstream effects of treatment with either agent reduces cell and CSC survival, as
well as activation of pathways downstream of Notch including NF-κB (152,158,172).
The effect of DATS on Notch signaling pathway has not been identified in breast
cancer cells.
We show in our results that DATS inhibits viability, clonogenic survival, alpha
secretases, and Notch ligands in breast cancer cells. We assessed the effect of DATS
on cell viability in estrogen-dependent and estrogen-independent breast cancer cell
lines and found that DATS induced a dose-dependent decrease in cell growth in
breast cancer cells independent of estrogen receptor expression. Importantly, normallike breast epithelial cells were more resistant to DATS, suggesting that normal breast
tissue is affected by DATS treatment to a lesser extent compared to breast cancer
cells.
In addition, we observed that DATS had a long-lasting effect on the proliferative
capacity of breast cancer cells. The mechanism by which DATS chronically inhibits
cancer cell proliferation after short exposure periods requires further investigation.
Published literature has shown that DATS inhibits the breast CSC population (34).
Additionally, in osteosarcoma cells DATS induces expression of microRNA-34a, 143, -145, and -200b/c, which play roles in tumor suppression (47). Modulation of
CSCs and microRNA networks are two possible mechanisms by which DATS has a
sustained effect on cancer cell proliferation in our clonogenic assay, and
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carcinogenesis in humans (31). The role of DATS in modulation of epigenetic marks,
e.g. methylation and acetylation, in cancer cells requires future research, but serves as
another potential explanation of the lasting effects of DATS treatment in cells and
humans.
We report that DATS targets the alpha secretases ADAM10 and ADAM17, and
the Notch ligands Jagged-1 and Jagged-2 in breast cancer cells. ADAM10 and
ADAM17 are each inversely associated with survival in breast cancer, and play a
critical role in Notch pathway activation (65,66,226). Jagged-1 and Jagged-2 play
instrumental roles in Notch pathway initiation, and are frequently overexpressed in
invasive breast cancer compared to normal breast tissue (58). We therefore conclude
that our data show inhibition of significant and relevant proteins in breast cancer cells,
and support further investigation of DATS in preclinical models of breast cancer
progression.
The mechanism by which DATS inhibits expression of ADAM10 and
ADAM17 in breast cancer cells requires future research. Our results do not show a
strong inhibitory effect of DATS on ADAM10 mRNA, suggesting that inhibition of
ADAM10 protein occurs at the translational level, post-translational level, or some
combination of the two. Furthermore, our results suggest that DATS more robustly
inhibits expression of active ADAM10 compared to the ADAM10 precursor,
indicating that DATS may play a role in inhibiting expression or activity of
proprotein convertase-7 or furin. Future research determining the effect of DATS on
proprotein convertase-7 and furin expression and activity, as well as on degradation
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of ADAM10 and ADAM17 will provide valuable information of DATS’s mechanism
of action against alpha secretases in cancer cells.
Successful use of DATS in a clinical setting will require a broader
understanding of its anticancer effects in cell and animal models and its
pharmacokinetics in humans. Animal models identifying the effect of DATS on
ADAM10 expression in tumor tissue are essential. In addition, the safety of DATS
combined with anticancer drugs must be tested in animal models, as toxic drug-drug
interactions may limit overall treatment efficacy. Understanding DATS
pharmacokinetics is required for evaluation of DATS as an anticancer agent in
humans. Identifying the process of gut absorption and subsequent metabolism or
storage of DATS in body organs will broaden our understanding of potential
requirements for modified DATS analogs or drug delivery systems which extend the
half-life and clinical efficacy of the drug in humans. While some clinical data are
available (31), pharmacokinetic evaluation of DATS will also reveal levels of DATS
which are safe for human consumption. The results of the present study contribute to
a growing body of basic evidence to support further investigation of DATS as an
anticancer agent in breast cancer.
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